Literature DB >> 15614047

Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation.

Mario Otto1, Raymond C Barfield, Rekha Iyengar, Janet Gatewood, Ingo Müller, Martha S Holladay, Jim Houston, Wing Leung, Rupert Handgretinger.   

Abstract

Human gammadelta T cells are a small fraction of T cells that have been shown to exert major histocompatibility (MHC)-unrestricted natural cytotoxicity against a variety of solid tumors and some subsets of leukemias and lymphomas. They are also involved in the immune response to certain bacterial, viral, and parasitic infections and expand significantly in CMV- or HSV-infected organ allografts. They are able to mediate antibody-dependent cytotoxicity and are not alloreactive, which makes them attractive candidates for cell-based immunotherapy. However, their frequency in peripheral blood is low and ex vivo expansion of gammadelta T cells is labor-extensive, does not always yield cells with full innate cytotoxic power, and has the potential for microbial contamination. Therefore, the authors developed a clinical-scale, automated cell purification method for the efficient enrichment of gammadelta T cells from leukapheresis products. Six leukapheresis products were purified for gammadelta T cells using a single-step immunomagnetic method. Purity and phenotype were assessed by flow cytometry. A standard Europium release assay was performed to determine the cytotoxic capacity of the cells. Cytokine production was measured using a multiplex sandwich immunoassay. The mean percentage of gammadelta T cells in the final product was 91%, with an average recovery of 63%. The cells showed a high co-expression of CD8, CD56, CD28, and CD11b/CD18. In some products an unusually high proportion of Vgamma9Vdelta1 T cells was found. The isolated cells were cytotoxic against the neuroblastoma cell line NB1691 and the erythroleukemic line K562 in vitro. They were able to produce a variety of immunomodulatory cytokines such as IFNgamma, TNFalpha, and MIP-1beta, but also GM-CSF and G-CSF when co-incubated in culture with and without various stimuli. In summary, the authors describe a rapid, automated, and efficient method for the large-scale enrichment of human gammadelta T cells. The cytotoxic properties of the cells were preserved. This method yields sufficient purified gammadelta T cells for use in adoptive immunotherapy as well as laboratory investigations and animal studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15614047     DOI: 10.1097/00002371-200501000-00009

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  10 in total

1.  Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.

Authors:  Nichole L Bryant; G Yancey Gillespie; Richard D Lopez; James M Markert; Gretchen A Cloud; Catherine P Langford; Hilal Arnouk; Yun Su; Hilary L Haines; Catalina Suarez-Cuervo; Lawrence S Lamb
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

2.  Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients.

Authors:  P Lang; T Feuchtinger; H-M Teltschik; W Schwinger; P Schlegel; M Pfeiffer; M Schumm; A-M Lang; B Lang; C P Schwarze; M Ebinger; C Urban; R Handgretinger
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 3.  Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it?

Authors:  Gregory A Hale
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

4.  A novel subset of helper T cells promotes immune responses by secreting GM-CSF.

Authors:  J Zhang; A I Roberts; C Liu; G Ren; G Xu; L Zhang; S Devadas; Yufang Shi
Journal:  Cell Death Differ       Date:  2013-09-27       Impact factor: 15.828

5.  Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection.

Authors:  Sanja Vodanovic-Jankovic; William R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2006-11       Impact factor: 5.742

Review 6.  TCR αβ+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data.

Authors:  Kieran Sahasrabudhe; Mario Otto; Peiman Hematti; Vaishalee Kenkre
Journal:  Leuk Lymphoma       Date:  2018-09-06

Review 7.  γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends.

Authors:  Mateus de Souza Barros; Nilberto Dias de Araújo; Fábio Magalhães-Gama; Thaís Lohana Pereira Ribeiro; Fabíola Silva Alves Hanna; Andréa Monteiro Tarragô; Adriana Malheiro; Allyson Guimarães Costa
Journal:  Front Immunol       Date:  2021-09-22       Impact factor: 7.561

8.  Enrichment of human Vγ9Vδ2 T lymphocytes by magnetic poly(divinylbenzene-co-glycidyl methacrylate) colloidal particles conjugated with specific antibody.

Authors:  Piamsiri Sawaisorn; Tienrat Tangchaikeeree; Duangporn Polpanich; Panuwat Midoeng; Rachanee Udomsangpetch; Abdelhamid Elaissari; Kulachart Jangpatarapongsa
Journal:  RSC Adv       Date:  2018-04-17       Impact factor: 4.036

Review 9.  Gamma delta T-cell reconstitution after allogeneic HCT: A platform for cell therapy.

Authors:  Ahmed Gaballa; Lucas C M Arruda; Michael Uhlin
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

Review 10.  Recent developments in cell-based immune therapy for neuroblastoma.

Authors:  Michael R Verneris; John E Wagner
Journal:  J Neuroimmune Pharmacol       Date:  2007-03-02       Impact factor: 7.285

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.